S Morteza Seyed Jafari Laurence Feldmeyer Simon Bossart Dagmar Simon Christoph Schlapbach Luca Borradori
10.3389/fimmu.2020.611549
Front Immunol
2021 Jan 29;11:611549.
bullous pemphigoid dupilumab omalizumab recalcitrant treatment
CC BY
https://pubmed.ncbi.nlm.nih.gov/33584689/
Antibodies, Monoclonal, Humanized / therapeutic use Omalizumab / therapeutic use Pemphigoid, Bullous / drug therapy Skin / drug effects
Antibodies, Monoclonal, Humanized / therapeutic use Omalizumab / therapeutic use Pemphigoid, Bullous / drug therapy Skin / drug effects Case Reports Research Support, Non-U.S. Gov't Aged Drug Therapy, Combination Humans Male Pemphigoid, Bullous / diagnosis Pemphigoid, Bullous / immunology Remission Induction Skin / immunology Skin / pathology Treatment Outcome Antibodies, Monoclonal, Humanized Omalizumab dupilumab
PMC7879677
33584689
Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
2021